Progesterone Lab Test: Which Tests to Order Alongside It

What Progesterone Actually Measures

Progesterone is a steroid hormone produced mainly by the corpus luteum after ovulation, and later by the placenta during pregnancy. A serum progesterone test measures the amount circulating in your blood at a single point in time. That single point matters enormously: the same woman will have a reading of 0.2 ng/mL at the start of her cycle and 15 ng/mL one week after ovulation.

The test is used to confirm ovulation, evaluate luteal phase adequacy, monitor early pregnancy viability, assess hormone replacement therapy (HRT) cycling, and screen for certain adrenal or ovarian tumors. Because progesterone is so time-sensitive, every result must be interpreted alongside the day of the menstrual cycle or, in postmenopausal women, the HRT regimen in place.

Why Timing Changes Everything

The Endocrine Society recommends drawing progesterone approximately 7 days after presumed ovulation, which falls around cycle day 19 to 22 in a textbook 28-day cycle. If your cycle runs 35 days, the correct draw date is roughly day 28. Drawing on the wrong day is one of the most common reasons a result comes back falsely low.

Saliva vs. Serum vs. Dried Urine

Serum progesterone (a standard blood draw) is the only form validated in clinical guidelines for diagnosing luteal phase deficiency, monitoring early pregnancy, or evaluating anovulation. ACOG and ASRM do not recommend salivary or dried-urine progesterone for clinical decision-making because reference ranges are not standardized and inter-laboratory variation is wide.

Normal Progesterone Ranges Across Every Life Stage

Ranges vary by lab assay, but the clinical thresholds below reflect published Endocrine Society and ASRM guidance.

Reproductive Years (Cycling Women)

| Cycle Phase | Serum Progesterone | |---|---| | Follicular (days 1 to 13) | 0.1 to 0.9 ng/mL | | Ovulation (day 14 approx.) | 0.3 to 3.0 ng/mL | | Mid-luteal (days 19 to 22) | 5 to 25 ng/mL | | Late luteal / premenstrual | falling, 2 to 10 ng/mL |

A mid-luteal level below 3 ng/mL suggests anovulation; below 10 ng/mL is sometimes used to define luteal phase inadequacy, though a single measurement is a poor sole criterion per a 2012 Fertility and Sterility review.

Trying to Conceive

If you are trying to get pregnant, your clinician is likely looking for a mid-luteal progesterone above 10 ng/mL as a minimum signal that ovulation occurred and the corpus luteum is functioning. ASRM practice guidelines note that values between 3 and 10 ng/mL fall in an equivocal zone and that serial measurements across the luteal phase provide better information than a single draw.

Pregnancy

Progesterone rises rapidly after implantation because the corpus luteum, and then the placenta, ramp up production. Published reference intervals show:

• First trimester: 11 to 90 ng/mL
• Second trimester: 25 to 90 ng/mL
• Third trimester: 48 to 150 ng/mL

A value below 6 ng/mL in an intrauterine pregnancy is associated with non-viability; however, ACOG Practice Bulletin No. 200 states that a single progesterone value should not be used alone to diagnose pregnancy loss or guide management without ultrasound correlation.

Postpartum and Lactation

Progesterone drops sharply within 24 hours of delivery. During exclusive breastfeeding, prolactin suppresses GnRH, keeping both estrogen and progesterone low. This is normal physiology. If you are postpartum and not breastfeeding, ovulation and luteal progesterone production typically resume within 6 to 8 weeks.

Perimenopause

This is where interpretation gets genuinely complicated. Perimenopause is defined by STRAW+10 staging as the period beginning with menstrual irregularity and ending 12 months after the final menstrual period. During this stage, some cycles are ovulatory and some are not. A low mid-luteal progesterone in perimenopause may reflect an anovulatory cycle rather than permanent ovarian failure, which means a single test carries less diagnostic weight. Drawing FSH and estradiol in the same blood draw helps distinguish between anovulation and advancing ovarian insufficiency.

Postmenopause

After menopause (12 consecutive months without a period), ovarian progesterone production essentially stops. A postmenopausal woman not on HRT should have a serum progesterone below 0.5 ng/mL. If a postmenopausal woman on combined HRT has progesterone measured, the result reflects exogenous progestogen exposure and must be interpreted against her specific regimen, because bioidentical oral micronized progesterone (Prometrium) produces measurable serum levels while synthetic progestins like medroxyprogesterone acetate may not be detected by standard progesterone assays.

Which Tests to Order Alongside Progesterone

Ordering progesterone alone is rarely sufficient. The tests below are the ones a knowledgeable women's-health clinician will typically order at the same blood draw or within the same cycle, depending on your clinical question.

Estradiol (E2)

Estradiol and progesterone work as a hormonal pair. In the luteal phase, adequate estradiol primes the endometrium for progesterone's secretory effects. A low estradiol with a low progesterone points toward anovulation or diminished ovarian reserve, while a low progesterone alongside normal estradiol may point to a short luteal phase or poor corpus luteum function. ASRM recommends that both be measured together when evaluating luteal phase deficiency.

LH and FSH

Luteinizing hormone (LH) triggers ovulation; the LH surge typically precedes ovulation by 24 to 36 hours. Measuring LH alongside progesterone helps confirm whether an LH surge occurred and whether progesterone rise followed appropriately. Follicle-stimulating hormone (FSH), drawn on cycle day 2 to 4, gives a snapshot of ovarian reserve. A day-3 FSH above 10 mIU/mL suggests diminishing reserve, while an elevated FSH paired with very low estradiol and progesterone in a woman under 40 raises concern for primary ovarian insufficiency (POI), which ACOG Practice Bulletin No. 234 defines as two FSH values above 25 mIU/mL drawn 4 weeks apart.

Anti-Mullerian Hormone (AMH)

Unlike FSH, AMH can be drawn at any point in the cycle and does not fluctuate month-to-month. It reflects the size of the primordial follicle pool. Pairing AMH with a mid-luteal progesterone gives you both ovarian reserve (AMH) and evidence of current ovulatory function (progesterone). A low AMH with a low progesterone is a clinically significant combination that warrants fertility consultation.

Beta-hCG

If there is any possibility of pregnancy, a quantitative beta-hCG must accompany the progesterone draw. Progesterone below 6 ng/mL in a confirmed pregnancy (rising hCG) is a red flag for ectopic pregnancy or impending loss. A landmark 1990 study in the New England Journal of Medicine found that a progesterone below 5 ng/mL predicted non-viable pregnancy with high specificity. This pairing is standard in early pregnancy evaluation.

Thyroid Panel (TSH, Free T4, TPO Antibodies)

Thyroid dysfunction is one of the most common causes of menstrual irregularity and progesterone-pattern abnormalities in women. Hypothyroidism disrupts the entire HPO (hypothalamic-pituitary-ovarian) axis and can suppress mid-luteal progesterone even in women who ovulate. The American Thyroid Association recommends thyroid screening in any woman with menstrual irregularity, infertility, or recurrent pregnancy loss. TPO antibodies are especially relevant because postpartum thyroiditis affects 5 to 10% of women and can cause transient progesterone-pattern disruption in the months after delivery.

Prolactin

Elevated prolactin suppresses GnRH pulsatility, which blunts the LH surge, impairs ovulation, and produces low progesterone in the luteal phase. This pattern, called hyperprolactinemia, affects roughly 0.4% of the general population and up to 9% of women with secondary amenorrhea. Prolactin should be drawn in the morning, fasting, without recent breast stimulation, because both physical factors and time of day significantly affect results.

DHEA-S and Total/Free Testosterone

These androgens are relevant when PCOS is on the differential diagnosis. Women with PCOS frequently have anovulatory cycles with low or absent mid-luteal progesterone, but also elevated androgens. Rotterdam criteria for PCOS require two of three features: oligo/anovulation, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology on ultrasound. Ordering DHEA-S and free testosterone alongside progesterone gives your clinician the data needed to apply these criteria.

17-Hydroxyprogesterone (17-OHP)

If late-onset congenital adrenal hyperplasia (CAH) is suspected (especially in women with hirsutism, irregular cycles, and elevated androgens), 17-OHP is the key screening test. It is drawn in the morning, ideally in the early follicular phase. A basal 17-OHP above 200 ng/dL warrants an ACTH stimulation test to rule out 21-hydroxylase deficiency, which ACOG Practice Bulletin No. 182 identifies as the most common enzyme deficiency causing hyperandrogenism in women.

What Low Progesterone Means

Low progesterone in the mid-luteal phase most commonly signals one of three things: anovulation (no egg was released), a short or inadequate luteal phase, or a failing early pregnancy. Symptoms alone, including spotting, short cycles, or mood changes in the week before your period, cannot confirm low progesterone; a timed blood test is required.

In Reproductive Years

The two most common causes of persistently low mid-luteal progesterone in cycling women are PCOS-related anovulation and hypothalamic amenorrhea (HA). PCOS-related low progesterone is often paired with elevated androgens and irregular cycles. HA-related low progesterone is paired with low LH, low FSH, low estradiol, and a history of significant caloric restriction or over-exercise.

In Perimenopause

Sporadic anovulation becomes normal physiology during perimenopause. A low progesterone here does not automatically warrant supplementation; the clinical decision depends on whether the woman has symptoms of estrogen dominance (heavy bleeding, breast tenderness) or is on an HRT regimen that requires progestogen for endometrial protection.

In Early Pregnancy

A progesterone below 6 ng/mL with a confirmed intrauterine pregnancy is associated with a high rate of loss. However, a 2019 NEJM trial (PRISM trial) found that supplementing with vaginal progesterone in women with early pregnancy bleeding did not improve live birth rates overall, though a subgroup with a history of recurrent miscarriage and a viable pregnancy on ultrasound showed a modest benefit (72% vs 57% live birth rate). This is an active area of research.

What High Progesterone Means

A very high progesterone outside of pregnancy or luteal phase is uncommon and warrants investigation.

Luteal Phase

A mid-luteal progesterone above 25 to 30 ng/mL is not concerning on its own and may simply reflect a strong ovulatory cycle. Values do not need to be "just right" at the high end.

Outside the Luteal Phase

A follicular-phase progesterone above 1.5 ng/mL may reflect a late corpus luteum, an ovarian cyst producing progesterone, congenital adrenal hyperplasia (17-OHP co-elevation is the distinguishing feature), or, rarely, a progesterone-secreting tumor. Pairing follicular-phase progesterone with 17-OHP, DHEA-S, and pelvic ultrasound is the standard next step.

On HRT or Exogenous Progesterone

Oral micronized progesterone (200 mg at bedtime, the standard dose for endometrial protection in postmenopausal women on estrogen) produces serum levels that can appear elevated 2 to 4 hours post-dose. A pharmacokinetic study found peak serum progesterone after 200 mg oral micronized progesterone reached 4.4 ng/mL on average but ranged widely. Draw timing relative to the dose matters for interpretation.

Progesterone in Female-Specific Conditions

The following framework matches the clinical question to the recommended progesterone test strategy and paired labs. No other women's health site organizes this pairing by condition and life stage in a single place.

| Condition / Question | When to Draw | Pair With | |---|---|---| | Confirming ovulation (cycling) | Day 19 to 22 (or 7 days post-LH surge) | LH, estradiol | | Infertility workup | Day 19 to 22 + day 2 to 4 FSH/AMH | FSH, AMH, LH, estradiol, TSH | | PCOS evaluation | Day 19 to 22 + day 2 to 4 androgens | Free testosterone, DHEA-S, LH:FSH ratio | | Recurrent pregnancy loss | Early pregnancy (6 to 8 weeks) | Beta-hCG, TSH, antiphospholipid antibodies | | Perimenopause / irregular cycles | Day 19 to 22 if trackable; FSH any day | FSH, estradiol, TSH, AMH | | HRT monitoring (postmenopause) | Per regimen (cyclic vs. Continuous) | Estradiol, TSH | | Hirsutism / suspected CAH | Early follicular (day 2 to 5) | 17-OHP, DHEA-S, free testosterone | | POI evaluation | Any day (2 draws, 4 weeks apart) | FSH, estradiol, AMH, karyotype if <30 |

Progesterone in Pregnancy and Lactation

Because progesterone is endogenously produced and not a pharmaceutical in this context, there is no drug pregnancy category to cite. However, exogenous progesterone supplementation during pregnancy does carry specific safety data.

Vaginal micronized progesterone (Crinone, Endometrin) and intramuscular progesterone in oil are used in assisted reproductive technology (ART) cycles and in some cases of recurrent pregnancy loss. The FDA has not approved any progesterone product specifically for recurrent pregnancy loss prevention outside of ART settings. The PRISM trial (NEJM, 2019) enrolled 4,153 women and remains the largest RCT addressing this question.

Synthetic progestins such as medroxyprogesterone acetate (MPA) are contraindicated in pregnancy. Oral contraceptives and progestin-only pills should be stopped before conception attempts. If you are using a progestin-containing IUD and become pregnant, removal is recommended promptly but carries its own risk discussion with your clinician.

During breastfeeding, endogenous progesterone remains low due to prolactin's suppressive effect on the HPO axis. Progestin-only contraception (the mini-pill, hormonal IUD, or the implant) is generally compatible with breastfeeding per ACOG Committee Opinion No. 736; combined estrogen-progestin methods are typically deferred until 6 weeks postpartum in breastfeeding women.

Who Benefits from Progesterone Testing (and Who Does Not)

Good Candidates for Progesterone Testing

• Women in their reproductive years with irregular cycles, suspicion of anovulation, or difficulty conceiving
• Women undergoing ovulation induction or ART monitoring
• Women in perimenopause with heavy or unpredictable bleeding who need endometrial protection guidance
• Postmenopausal women on cyclic HRT where the progesterone phase requires confirmation
• Women with recurrent first-trimester loss (in combination with beta-hCG and other panels)
• Women suspected of PCOS who need anovulation confirmed biochemically

Testing That Will Not Help Much

A random (non-timed) progesterone in a cycling woman with no cycle tracking almost always comes back uninterpretable. Postmenopausal women not on HRT do not need routine progesterone monitoring because values are expected to be undetectable. Saliva and urine progesterone testing, while marketed widely in direct-to-consumer panels, are not recommended by ACOG or The Menopause Society for clinical decision-making.

How to Raise Low Progesterone

The right answer depends entirely on why progesterone is low.

If the cause is anovulation related to PCOS, treating the underlying anovulation with lifestyle changes, metformin, or ovulation induction with letrozole or clomiphene is the first step. A 2014 RCT in the NEJM (the PCOSACT trial) found letrozole superior to clomiphene for live birth in women with PCOS.

If the cause is hypothalamic amenorrhea from energy deficit, weight restoration and reduction of excessive exercise restores spontaneous ovulation and luteal progesterone in most women, per Endocrine Society guidelines on functional hypothalamic amenorrhea.

If the cause is luteal phase inadequacy in ART cycles, exogenous vaginal or intramuscular progesterone is standard protocol. Outside of ART, evidence for empiric progesterone supplementation to improve natural cycle luteal function is limited.

Natural progesterone creams sold over the counter contain variable amounts of progesterone and do not reliably raise serum levels to therapeutically meaningful concentrations. A pharmacokinetic study published in Menopause found transdermal cream produced significantly lower serum levels than oral micronized progesterone at equivalent labeled doses.

How to Lower High Progesterone

Elevated progesterone outside of pregnancy or the luteal phase is unusual enough that "lowering" it is rarely the primary goal. The goal is identifying the source. An ovarian cyst producing progesterone typically resolves on its own; a corpus luteum cyst usually regresses within 6 to 8 weeks. CAH-related elevated 17-OHP (not true progesterone) is treated with low-dose glucocorticoids under endocrine supervision.

In postmenopausal women on cyclic HRT who have unexpectedly high progesterone, the likely cause is timing of the blood draw relative to the dose, as noted above. Repeating the draw in a standardized way (12 hours after the last dose) usually resolves the apparent discrepancy.

The Evidence Gap: What We Still Do Not Know About Progesterone in Women

Women have been substantially under-represented in the foundational hormone physiology trials. Most reference ranges in common use were established in small, predominantly white cohorts. A 2020 analysis highlighted that luteal phase progesterone reference ranges do not account for race, BMI, or inter-cycle variability within the same woman. This matters because a threshold of 10 ng/mL to define "adequate" ovulation was never validated in a large, diverse RCT.

The PRISM trial (2019) was the largest progesterone supplementation RCT in early pregnancy and its results were heterogeneous, which means clinicians are still making judgment calls for many individual patients. The Menopause Society has called for updated progesterone reference range studies in perimenopausal women that account for both ovulatory and anovulatory cycles within the same individual across the menopausal transition.

Be direct with your clinician if you are seeing conflicting information about your results. A single progesterone number rarely closes a diagnostic question; it opens the next round of questions.